1stOncology™: Cancer Intelligence Service – Page 9104 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ISSCR 2021 – The Global Stem Cell Event Virtual, June 21, 2021

On June 29, 2021 Bioneer reported to participating to the ISSCR 2021, the Global Stem Cell Event Virtual, on June 21st and presenting at the focus session on developments to simplify and accelerate iPSC research with EBiSC (Press release, Bioneer, JUN 29, 2021, View Source [SID1234584840]).
The presentation if part of the Focus Sessions of the ISSCR Annual Meeting, where Dr. Benjamin Schmid and Dr. Mikkel Rasmussen from Bioneer will be presenting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Focus Sessions provide in-depth coverage of specific topics of interest and are presented by interested academic and industry groups. These educational opportunities in science, society, and education are organized by members and open to all meeting attendees. Sessions are held live, with Q&A and chat, and will be available as on-demand programming for 30 days after the meeting.

The Focus Session on developments to simplify and accelerate iPSC research is organized by The European Bank for induced Pluripotent Stem Cells (EBiSC).

The European Bank for iPSCs (EBiSC) is a centralized repository, currently in a second project phase including both non-profit and commercial iPSC researchers (EBiSC2), working to make iPSC tools available and developing protocols which improve and simplify their use. This focus session will share how EBiSC2 partners are adapting and consolidating iPSC expansion, differentiation and cryopreservation approaches to help ease transition into high volume applications whilst also ensuring accessibility for non-expert users. We will discuss how the inclusion of iPSC tool lines in these protocol developments enables rapid generation of functionally mature derived cell types and how the associated iPSC datasets can be broadly shared in an ethically compliant manner. Lastly, common stumbling blocks will be discussed to raise awareness across the community.

See below the full program of the session:

The European Bank for iPSCs Program

Julia Neubauer, PhD, Fraunhofer-IBMT, Germany
Alfredo Cabrera-Socorro, PhD, Janssen Pharmaceutica NV, Belgium
Welcome and Overview

Julia Neubauer, PhD, Fraunhofer-IBMT, Germany
Approaches Towards Expansion, Differentiation and Banking Of iPSCs At High Volume

Mikkel Rasmussen, PhD, Bioneer, Denmark
Emilie Lemesre, PhD, Servier, France
iPSC-Derived Hepatocytes in Drug Screening and Toxicology

Alfredo Cabrera-Socorro, PhD, Janssen Pharmaceutica NV, Belgium
Development of A Fully Human Neuronal and Astrocyte Co-Culture Assay Amenable For Electrophysiological Studies In Functionally Mature Neurons

Benjamin Schmid, PhD, Bioneer, Denmark
Gene-Editing in iPSCs – Unexpected Pitfalls: On-Target Effects

Andreas Kurtz, PhD, Fraunhofer-IBMT, Germany
Collection, Standardisation and Sharing Of iPSC Associated Datasets Using Open Tools

Eugenia Jones, PhD, Fujifilm Cellular Dynamics, USA
Common Non-Scientific Challenges in The Generation, Use and Sharing Of iPSC Lines.

Panel Discussion: Upcoming Challenges In iPSC Research from An Academic and Industry Perspective.

Nordic Life Science Days digital conference, April 20-23, 2021

On June 29, Bioneer reported that we will be participating in the Nordic Life Science Days 2021, from April 20th to 23rd (Press release, Bioneer, JUN 29, 2021, View Source [SID1234584839]).

Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. This year the event will be in a digital format, where Bioneer will have a virtual booth, where you will find all information about our company and our high quality service.

You can book a meeting with our Sales and Business Development Manager Lovisa Sunesson on the Nordic Life Science Days platform, contact us via the available online chat or by mail .

Moreover you will be able to hear more about our company and specifically our disease modelling in our company presentation featuring Christian Clausen, Chief Scientific Officer at Bioneer.

Introducing Bioneer’s new R&D programs for 2021-2024

On June 29, 2021 Bioneer reported that has initiated two very exciting and ambitious R&D programs that during the next four years will strengthen our capabilities and service solutions that we offer to life science companies (Press release, Bioneer, JUN 29, 2021, View Source [SID1234584838]). We look forward to seeing our R&D organization move these programs forward and be able to assist a broad range of companies with the best services that can contribute to new therapies and medicines.
The first program within "In Vitro Modelling" aims at developing a new generation of in vitro models within CNS, immunology, cancer and the gastro-intestinal system. Our ambition is to develop the best-in-class in vitro models matching the industry needs where especially the CNS track will take us into the area of screening and automation. We are also excited to enter the fast-moving field of Artificial Intelligence that we will couple to our new generation of in vitro models.

The other R&D program within "Early Stage Development of Drug Candidates" will further strengthen our ambition to assist companies from "gene to protein" and with peptide and small molecule development. This ambitious program will move our capabilities in the field of recombinant protein manufacturing to a new level both in terms of production efficiency and the ability to complete CMO transfers. We also look into the exciting world of peptides, where we will use our strong formulation competences to strengthen the service offering.

Bioneer encourages companies, universities and hospitals to contact us. If you would like to know more about the R&D programs, learn how you could benefit from the development activities, or would like to collaborate on one of the topics, feel free to contact CSO Christian Clausen (e-mail).

Entry into a Material Definitive Agreement.

On June 29, 2021, Intellia Therapeutics, Inc. (the "Company" or "Intellia") reported that it entered into an Underwriting Agreement (the "Underwriting Agreement") with Goldman Sachs & Co LLC, Jefferies LLC, SVB Leerink LLC, and Barclays Capital Inc. as representatives of the several underwriters listed on Schedule A thereto (the "Underwriters"), related to a public offering (the "Offering") of 4,137,931 shares of common stock of the Company, par value $0.0001 per share (the "Common Stock") at a price to the public of $145.00 per share (Filing, 8-K, Intellia Therapeutics, JUN 29, 2021, View Source [SID1234584582]). In addition, the Company granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 620,689 shares, which option was exercised in full on June 30, 2021. The Company estimates that the net proceeds from the offering will be approximately $648.1 million, including the additional shares, after deducting the underwriting discount and its estimated offering expenses. The offering is expected to close on July 2, 2021, subject to customary closing conditions.

The Company made certain customary representations, warranties and covenants concerning the Company and the registration statement in the Underwriting Agreement and also agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-251022), including the prospectus dated November 30, 2020, as supplemented by a prospectus supplement dated June 29, 2021. This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any of the shares of Common Stock.

The foregoing description of certain terms of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Underwriting Agreement, which is attached as Exhibit 1.1 hereto and is incorporated by reference herein. A copy of the opinion of Goodwin Procter LLP, relating to the legality of the ordinary shares, is filed as Exhibit 5.1 hereto and is incorporated by reference herein.

Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership

On June 29, 2021 Curaleaf International (formerly EMMAC Life Sciences Group), Europe’s largest vertically integrated cannabis company, reported that its wholly owned subsidiary, Adven GmbH ("Adven"), has announced a strategic partnership with Zambon GmbH, the German subsidiary of Zambon Spa, an Italian multinational pharmaceutical company, leading in Parkinson’s Diseases, Severe Respiratory Diseases and Pain (Press release, EMMAC Life Sciences, JUN 29, 2021, View Source [SID1234584505]). The aim of the agreement is to make medical cannabis treatments available to patients.The first treatment will be launched in Germany in Summer 2021.

"We are delighted to be announcing this partnership with Zambon today, and to be working with a leading pharmaceutical company to create the first European pharmaceutical and medical cannabis partnership; we believe it is testament to our continued commitment to research-led product excellence at Curaleaf International," says Curaleaf International CEO, Antonio Costanzo. "We are looking forward to strengthening our collaboration and the creation of more such partnerships, where relevant pharmaceutical and medical cannabis expertise and excellence can be combined to advance the industry’s understanding of medical cannabis for the rapidly growing European patient community."

"Supporting therapies, like medical cannabis, are a meaningful addition to Zambon’s European portfolio. Our expertise in neurology and Curaleaf International’s knowledge of the pharmaceutical active processes of cannabinoids provide ideal conditions to bring innovative treatment to patients," says Marco Castino, Head of Region Europe in Zambon.

The market for medical cannabis in Germany

Since 2017, cannabis has been approved for therapeutic use in Germany and may be prescribed by doctors for serious illnesses. Germany is Europe’s largest market for medical cannabis. It is expected to be worth USD 2.1 billion[1] by 2025.

"We are constantly seeking ways to enhance the life of chronically neurologically ill patients with our products. Offering modern therapy approaches, such as co-medication, especially in view of the progression of these clinical pictures, is part of our vision to improve patients‘ lives" says Dirk Greshake, Zambon GmbH General Manager.

"As strategic partners, we are combining our experience and resources for the benefit of the patient. Together we want to advance the development of high-quality medicinal cannabis and have made it our mission to improve the quality of life of neurological patients who still have symptoms despite conventional therapy. With Zambon‘s many years of experience as a research company in the field of neurology and Adven GmbH, as part of Curleaf International, Europe’s largest vertically integrated medical cannabis company with its comprehensive expertise in the development and production of medicinal cannabis, we believe we have a unique partnership in place to address these patient requirements," explains Julian Vaterrodt, CEO of Adven GmbH.